Interestingly, the clinical features of neuropathic LSDs are similar to those described in SPG48 patients (3,12,13), as well as SPG11 and SPG15, including cognitive impairment, ataxia, peripheral neuropathy, parkinsonism and spasticity (42). Here, SPG11 is linked to Parkinson disease.